ANZUP trials coming soon
Trials coming soon Prostate Cancer: EVOLUTION (ANZUP 2001) EVOLUTION PRINCIPAL INVESTIGATOR, ASSOCIATE PROFESSOR SHAHNEEN SANDHU
A Phase II Trial of dual Immunotherapy and Lu-PSMA in metastatic castration resistant prostate cancer (mCRPC)
Although men with metastatic prostate cancer initially respond to hormone treatments, many will develop castration-resistant prostate cancer, i.e., their cancer continues to grow despite hormone treatment. This condition is called mCRPC. Immunotherapy and Lutetium-177 PSMA (Lu-PSMA for short) are two treatments that we hope might help men in this situation. Ipilimumab and nivolumab are immunotherapy drugs that activate the body’s own immune response to kill cancer cells. Both ipilimumab and nivolumab allow the immune system to “see” the cancer, seek it out and destroy it. These treatments are given intraveneously (IV) and have been effective in treating other cancers like melanoma, kidney and lung cancers, but studies of ipilimumab and nivolumab in men with prostate cancer remain experimental at present.
Prostate Cancer: DIPPER (ANZUP 2002) A multi-centre, randomised phase 2 clinical trial of early salvage radiotherapy versus surveillance for biochemical recurrence after radical prostatectomy incorporating clinical and imagingbased risk stratification.
DIPPER PRINCIPAL INVESTIGATOR, DR MATT ROBERTS
Current best standard treatment for prostate cancer following radical prostatectomy is uncertain. Previous studies using traditional imaging methods, including computed tomography (CT) and bone scan, showed that radiation therapy was the best way to control PSA levels and return of cancer where the prostate was previously located (local recurrence). Whether radiation therapy reduced the spread of cancer around the body (metastases) or prolonged life (overall survival) was not conclusively proven. Use of radiation therapy also can result in significantly unpleasant side effects, which can affect quality of life. Conversely, personalised selection of men for surveillance using pathology, blood and imaging tests may identify a group of men who can forego additional treatments for the same cancer outcome and avoid side effects. Currently in Australia, with widespread adoption of PSMA PET scanning, unfortunately clinicians cannot agree on the best approach.
Lu-PSMA is a type of treatment called radionuclide CYCLE, RUN OR WALK TO therapy that can be used to treat prostate cancer by OR bringing BELOW THE BELT CAN radioactive atoms into the cancer cells. Many
The main aim of the study is to see if using radiation therapy prostate cancers, in particular those that have spread or to the prostate bed and/or close lymph glands is better than ew campaign – Below the Belt #YourWay a become resistant to hormonal therapies, have a substance active surveillance for cancer control in a carefully selected n #YourWay as many km’s as you can. on their cell surface called prostate specific membrane group of men with low-risk features and negative PSMA antigen (PSMA). Lu-PSMA attaches to PSMA on the ome, at the office, or in great outdoors. PET the imaging. The study also aims to determine: surface of prostate cancer cells and delivers radiation eded funds for below the belt cancer resear i. the effect of study treatment on other measures of how to the cancer cell, without much radiation exposure to well the prostate cancer is controlled, other parts of the body. Recent studies have shown that ii. of life, alone. D effects of treatment on quality h work colleagues, with the a friend or Lu-PSMA is a promising treatment for men with metastatic ifferences in the costs of care for people on treatment, l in Australia and Newiii. d Zealand. prostate cancer that is no longer under control after iv. t ests that might identify people who are more or less several standard treatments. likely to benefit from treatment, and The aim of below this study is to see if combining ipilimumab v. practice patterns among clinicians,in participating 000 for the belt (bladder kidney, pe hospitals. and nivolumab with Lu-PSMA can further improve the anti-cancer effects of Lu-PSMA. It is thought that Recent studies show that radiation therapy leads to good e you ipilimumab to sign up to and nivolumab and Lu-PSMA may work this fantastic new campa cancer control rates, but almost halfe of men have until 2021. C y c l e # Y o u r W ay in st awill d . together to treat the cancer. Lu-PSMA can potentially acceptable control with no treatment. This phenomenon was kill cancer cells and break up the tumour into small s and help fund future clinical trials for bel shown in Australian and international clinical trials comparing pieces that may be recognised by your immune system this approach immediately after surgery (adjuvant versus while ipilimumab and nivolumab helps your immune early salvage radiation therapy), where similar cancer control ED IN FINDING OUT MORE system to be activated to find and attack your cancer. was observed overall but >60% of men avoided radiation This new treatment combination may lead to shrinkage R INTEREST HERE. therapy. This is the first randomised clinical trial evaluating or stabilisation of previously progressing tumours and the potential benefit of personalised patient selection and therefore hopefully stop or reverse the growth of your different treatments for your type of prostate cancer. We plan cancer. We plan to enrol 100 Australian men in this trial. to enrol almost 200 participants in the study in Australia.
e Belt, #YourWay
A LITTLE BELOW THE BELT 21
